Machine Learning-Driven Analysis of Individualized Treatment Effects Comparing Buprenorphine and Naltrexone in Opioid Use Disorder Relapse Prevention

被引:0
|
作者
Afshar, Majid [1 ]
Linck, Emma J. Graham [1 ]
Spicer, Alexandra B. [1 ]
Rotrosen, John [2 ]
Salisbury-Afshar, Elizabeth M. [1 ]
Sinha, Pratik [3 ]
Semler, Matthew W. [4 ]
Churpek, Matthew M. [1 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, 1685 Highland Ave, Madison, WI 53705 USA
[2] NYU, Grossman Sch Med, New York, NY USA
[3] Washington Univ, Sch Med, St Louis, MO USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
关键词
opioid use disorder; opioid treatment; heterogeneity of treatment effect; buprenorphine; naltrexone; EXTENDED-RELEASE NALTREXONE; RATING-SCALES; METHADONE; XBOT;
D O I
10.1097/ADM.0000000000001313
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Objective: A trial comparing extended-release naltrexone and sublingual buprenorphine-naloxone demonstrated higher relapse rates in individuals randomized to extended-release naltrexone. The effectiveness of treatment might vary based on patient characteristics. We hypothesized that causal machine learning would identify individualized treatment effects for each medication. Methods: This is a secondary analysis of a multicenter randomized trial that compared the effectiveness of extended-release naltrexone versus buprenorphine-naloxone for preventing relapse of opioid misuse. Three machine learning models were derived using all trial participants with 50% randomly selected for training (n = 285) and the remaining 50% for validation. Individualized treatment effect was measured by the Qini value and c-for-benefit, with the absence of relapse denoting treatment success. Patients were grouped into quartiles by predicted individualized treatment effect to examine differences in characteristics and the observed treatment effects. Results: The best-performing model had a Qini value of 4.45 (95% confidence interval, 1.02-7.83) and a c-for-benefit of 0.63 (95% confidence interval, 0.53-0.68). The quartile most likely to benefit from buprenorphine-naloxone had a 35% absolute benefit from this treatment, and at study entry, they had a high median opioid withdrawal score (P < 0.001), used cocaine on more days over the prior 30 days than other quartiles (P < 0.001), and had highest proportions with alcohol and cocaine use disorder (P <= 0.02). Quartile 4 individuals were predicted to be most likely to benefit from extended-release naltrexone, with the greatest proportion having heroin drug preference (P = 0.02) and all experiencing homelessness (P < 0.001). Conclusions: Causal machine learning identified differing individualized treatment effects between medications based on characteristics associated with preventing relapse.
引用
收藏
页码:511 / 519
页数:9
相关论文
共 50 条
  • [41] Mindfulness-Based Relapse Prevention with Individuals Receiving Medication-Assisted Outpatient Treatment for Opioid Use Disorder
    Keith J. Zullig
    Laura R. Lander
    Samantha Sloan
    Michael R. Brumage
    Gerry R. Hobbs
    Laurel Faulkenberry
    Mindfulness, 2018, 9 : 423 - 429
  • [42] Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk
    Tardelli, Vitor
    Xu, Kevin Y.
    Bisaga, Adam
    Levin, Frances R.
    Fidalgo, Thiago M.
    Grucza, Richard A.
    BMJ MENTAL HEALTH, 2023, 26 (01):
  • [43] Prescription Amphetamines in People With Opioid Use Disorder and Co-Occurring Psychostimulant Use Disorder Initiating Buprenorphine: An Analysis of Treatment Retention and Overdose Risk
    Tardelli, Vitor
    Xu, Kevin
    Bisaga, Adam
    Levin, Frances
    Fidalgo, Thiago
    Grucza, Richard
    DRUG AND ALCOHOL DEPENDENCE, 2024, 260
  • [44] A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder
    Sullivan, Maria A.
    Bisaga, Adam
    Pavlicova, Martina
    Carpenter, Kenneth M.
    Choi, C. Jean
    Mishlen, Kaitlyn
    Levin, Frances R.
    Mariani, John J.
    Nunes, Edward, V
    AMERICAN JOURNAL OF PSYCHIATRY, 2019, 176 (02): : 129 - 137
  • [45] Infectious Disease (ID) Learning Unit: What the ID Clinician Needs to Know About Buprenorphine Treatment for Opioid Use Disorder
    Westlake, Amanda A.
    Eisenberg, Mark P.
    OPEN FORUM INFECTIOUS DISEASES, 2017, 4 (01):
  • [46] Applied machine learning analysis: Factors correlated with injection drug use and post-prison medication for opioid use disorder treatment engagement
    Victor, Grant
    Roddy, Ariel
    Lenz, Danielle
    Willis, Tamarie
    Kubiak, Sheryl
    JOURNAL OF OFFENDER REHABILITATION, 2023, 62 (05) : 297 - 314
  • [47] Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder
    Marcus Björnsson
    Chayan Acharya
    Kerstin Strandgården
    Fredrik Tiberg
    Clinical Pharmacokinetics, 2023, 62 : 1427 - 1443
  • [48] Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder
    Bjornsson, Marcus
    Acharya, Chayan
    Strandgarden, Kerstin
    Tiberg, Fredrik
    CLINICAL PHARMACOKINETICS, 2023, 62 (10) : 1427 - 1443
  • [49] Enhancing wastewater treatment efficiency through machine learning-driven effluent quality prediction: A plant-level analysis
    Cechinel, Maria Alice Prado
    Neves, Juliana
    Fuck, Joao Vitor Rios
    Andrade, Rodrigo Campos de
    Spogis, Nicolas
    Riella, Humberto Gracher
    Padoin, Natan
    Soares, Cintia
    JOURNAL OF WATER PROCESS ENGINEERING, 2024, 58
  • [50] Association of Bupropion, Naltrexone, and Opioid Agonist Treatment With Stimulant-Related Admissions Among People With Opioid Use Disorder: A Case-Crossover Analysis
    Xu, Kevin Y.
    Mintz, Carrie M.
    Presnall, Ned
    Bierut, Laura J.
    Grucza, Richard A.
    JOURNAL OF CLINICAL PSYCHIATRY, 2022, 83 (04)